切换至 "中华医学电子期刊资源库"

中华老年病研究电子杂志 ›› 2023, Vol. 10 ›› Issue (03) : 35 -38. doi: 10.3877/cma.j.issn.2095-8757.2023.03.006

临床研究

SGLT2抑制剂对中老年糖尿病患者血清FGF21水平的影响
陈晓佩, 余丹, 潘君, 孔佳超, 李欢, 吴天凤()   
  1. 310013 杭州,浙江医院内分泌科
    310013 杭州,浙江医院检验科
  • 收稿日期:2023-03-28 出版日期:2023-08-28
  • 通信作者: 吴天凤
  • 基金资助:
    浙江省中医药科研基金项目(2021ZQ002、2022ZQ001); 浙江省医药卫生科技计划项目(2022KY465)

SGLT-2 inhibitors decrease serum FGF21 level in quinquagenarian diabetic patients

Xiaopei Chen, Dan Yu, Jun Pan, Jiachao Kong, Huan Li, Tianfeng Wu()   

  1. Department of Endocrinology, Zhejiang Hospital, Hangzhou 310013, China
    Department of Clinical Laboratory, Zhejiang Hospital, Hangzhou 310013, China
  • Received:2023-03-28 Published:2023-08-28
  • Corresponding author: Tianfeng Wu
引用本文:

陈晓佩, 余丹, 潘君, 孔佳超, 李欢, 吴天凤. SGLT2抑制剂对中老年糖尿病患者血清FGF21水平的影响[J/OL]. 中华老年病研究电子杂志, 2023, 10(03): 35-38.

Xiaopei Chen, Dan Yu, Jun Pan, Jiachao Kong, Huan Li, Tianfeng Wu. SGLT-2 inhibitors decrease serum FGF21 level in quinquagenarian diabetic patients[J/OL]. Chinese Journal of Geriatrics Research(Electronic Edition), 2023, 10(03): 35-38.

目的

探讨钠-葡萄糖协同转运蛋白2抑制剂(SGLT2i)对中老年2型糖尿病患者血清成纤维细胞生长因子21(FGF21)的影响。

方法

选取2021年10月至2023年2月在浙江医院就诊的50岁以上2型糖尿病患者54例,其中单用二甲双胍者28例(对照组),联用二甲双胍和SGLT2i者26例(观察组)。收集患者相关临床资料,包括糖尿病病程、体质指数、糖化血红蛋白、空腹血糖、血清C肽、低密度脂蛋白、三酰甘油、高密度脂蛋白、总胆固醇、尿酸、肌酐及血清FGF21水平等,应用独立t检验进行组间分析,并采用多元线性回归分析血清FGF21水平的独立影响因素。

结果

观察组糖尿病病程较对照组长(t=-4.650,P<0.01),血尿酸、FGF21水平较对照组低(t=2.645、4.399,P<0.05或0.01)。回归分析提示,SGLT2i治疗对血清FGF21水平的影响有统计学意义(t=-2.260,P<0.05)。

结论

SGLT2i治疗与中老年2型糖尿病患者血清FGF21水平的下降相关。

Objective

To explore the effects of sodium glucose co-transporter-2 inhibitor (SGLT2i) on the serum levels of fibroblast growth factor 21 (FGF21) in quinquagenarian diabetic patients.

Methods

Study was performed in 54 patients with type 2 diabetes in Zhejiang Hospital during October 2021 and February 2023. All patients aged over 50 years, including 28 patients treated with metformin (control group) and 26 patients treated with metformin and SGLT2i (experimental group). Diabetic course, body mass index, hemoglobin A1C, fasting blood glucose, fasting C-peptide, low density lipoprotein, triglycerides, high density lipoprotein, total cholesterol, uric acid, creatinine and serum FGF21 level were collected. Independent t test was applied for between-group analysis, and multiple linear regression was used to identify the independent influencing factors of serum FGF21 levels.

Results

Diabetic course was higher in experimental group than that in the control group (t=-4.650, P < 0.01), while uric acid and serum FGF21 level were lower than those in the control group (t=2.645 and 4.399, P < 0.05 or P < 0.01). Logistic regression analysis revealed that SGLT2i inhibitors therapy was independent risk factor for serum FGF21 level (t=-2.260, P < 0.05).

Conclusion

SGLT2i therapy was related with decreased serum FGF21 levels in quinquagenarian diabetic patients.

表1 两组患者基线资料的比较(±s
表2 两组患者治疗后各指标的比较(±s
表3 血清FGF21水平影响因素的多元线性回归分析
[1]
Chavda V, Vashi R, Patel S. Cerebrovascular complications of diabetes: SGLT-2 inhibitors as a promising future therapeutics[J]. Curr Drug Targets, 2021, 22(14):1629-1636.
[2]
Marilly E, Cottin J, Cabrera N, et al. SGLT2 inhibitors in type 2 diabetes: A systematic review and meta-analysis of cardiovascular outcome trials balancing their risks and benefits[J]. Diabetologia, 2022, 65(12):2000-2010.
[3]
Nuffield Department of Population Health Renal Studies Group; SGLT2 inhibitor Meta-Analysis Cardio-Renal Trialists' Consortium. Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: Collaborative meta-analysis of large placebo-controlled trials[J]. Lancet, 2022, 400(10365):1788-1801.
[4]
Flippo KH, Potthoff MJ. Metabolic messengers: FGF21[J]. Nat Metab, 2021, 3(3):309-317.
[5]
Tan H, Yue T, Chen Z, et al. Targeting FGF21 in cardiovascular and metabolic diseases: From mechanism to medicine[J]. Int J Biol Sci, 2023, 19(1):66-88.
[6]
Chen Z, Yang L, Liu Y, et al. The potential function and clinical application of FGF21 in metabolic diseases[J]. Front Pharmacol, 2022, 13:1089214.
[7]
中国老年2型糖尿病防治临床指南编写组,中国老年医学学会老年内分泌代谢分会,中国老年保健医学研究会老年内分泌与代谢分会,等.中国老年2型糖尿病防治临床指南(2022年版)[J].中华内科杂志202261(1):12-50.
[8]
Shi Q, Nong K, Vandvik PO, et al. Benefits and harms of drug treatment for type 2 diabetes: Systematic review and network meta-analysis of randomised controlled trials[J/OL]. BMJ, 2023, 381:e074068.
[9]
Szczepańska E, Gietka-Czernel M. FGF21: A novel regulator of glucose and lipid metabolism and whole-body energy balance[J]. Horm Metab Res, 2022, 54(4):203-211.
[10]
Osataphan S, Macchi C, Singhal G, et al. SGLT2 inhibition reprograms systemic metabolism via FGF21-dependent and -independent mechanisms[J/OL]. JCI Insight, 2019, 4(5):e123130.
[11]
Huang S, Wu B, He Y, et al. Canagliflozin ameliorates the development of NAFLD by preventing NLRP3-mediated pyroptosis through FGF21-ERK1/2 pathway[J/OL]. Hepatol Commun, 2023, 7(3):e0045.
[12]
Yamakage H, Tanaka M, Inoue T, et al. Effects of dapagliflozin on the serum levels of fibroblast growth factor 21 and myokines and muscle mass in Japanese patients with type 2 diabetes: A randomized, controlled trial[J]. J Diabetes Investig, 2020, 11(3):653-661.
[13]
Kosugi R, Nakatani E, Okamoto K, et al. Effects of sodium-glucose cotransporter 2 inhibitor (dapagliflozin) on food intake and plasma fibroblast growth factor 21 levels in type 2 diabetes patients[J]. Endocr J, 2019, 66(8):677-682.
[14]
Yan H, Xia M, Chang X, et al. Circulating fibroblast growth factor 21 levels are closely associated with hepatic fat content: A cross-sectional study[J]. PLoS One, 2011, 6(9):e24895.
[1] 曹雯佳, 刘学兵, 罗安果, 钟释敏, 邓岚, 王玉琳, 李赵欢. 超声矢量血流成像对2型糖尿病患者颈动脉壁剪切应力的研究[J/OL]. 中华医学超声杂志(电子版), 2024, 21(07): 709-717.
[2] 孟令凯, 李大勇, 王宁, 王桂明, 张炳南, 李若彤, 潘立峰. 袖状胃切除术对肥胖伴2型糖尿病大鼠的作用及机制研究[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 638-642.
[3] 李猛, 姜腊, 董磊, 吴情, 贾犇黎. 腹腔镜胃袖状切除术治疗肥胖合并2型糖尿病及脂肪胰的临床研究[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(05): 554-557.
[4] 刘盾, 潘晟. 不同入路腹腔镜袖状胃切除术用于肥胖症合并2型糖尿病的效果[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(02): 150-154.
[5] 赵帅, 王伟, 李瑞奇, 周家杰, 王道荣. 3D腹腔镜下袖状胃切除术治疗肥胖合并2型糖尿病的临床疗效及影响因素分析[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(02): 146-149.
[6] 陆文琪, 赵艳茹, 李焕娣, 樊欣娜, 王佳, 李萍. 2型糖尿病患者血清SMAD2和SOX6表达及其与蛋白尿的关系[J/OL]. 中华肾病研究电子杂志, 2024, 13(03): 145-151.
[7] 王星, 陈园, 热孜万古丽·乌斯曼, 郭艳英. T2DM、Obesity、NASH、PCOS共同致病因素相关的分子机制[J/OL]. 中华临床医师杂志(电子版), 2024, 18(05): 481-490.
[8] 王璇, 娜扎开提·尼加提, 雒洋洋, 蒋升. 皮肤晚期糖基化终末产物浓度与2型糖尿病微血管并发症的相关性[J/OL]. 中华临床医师杂志(电子版), 2024, 18(05): 447-454.
[9] 孙秀芹, 高美娟, 张琼阁, 吕凯敏, 王宏宇. 京西地区无心血管病史2型糖尿病中老年人群患心血管疾病的危险因素分析[J/OL]. 中华临床医师杂志(电子版), 2024, 18(03): 245-252.
[10] 孙琳, 韩萍萍, 张碧琳, 张军霞. 血清WISP1水平与2型糖尿病患者血尿酸升高的相关性[J/OL]. 中华临床医师杂志(电子版), 2024, 18(02): 178-182.
[11] 吴晓明, 翟仰魁, 王娟, 张硕, 许杰, 潘从清. 男性2 型糖尿病患者空腹C 肽和定量胰岛素敏感性检测指数与血浆致动脉粥样硬化指数的相关性[J/OL]. 中华肥胖与代谢病电子杂志, 2024, 10(04): 288-294.
[12] 吴子龙, 吴冰, 袁开盛, 胡瑞翔, 杨华, 王存川. 肥胖与胰腺疾病研究进展[J/OL]. 中华肥胖与代谢病电子杂志, 2024, 10(03): 213-219.
[13] 张梅, 陈卉, 李转霞, 王瑞, 李林娟. Metrnl和NLRP3炎症小体:糖尿病肾病的潜在诊断标志物[J/OL]. 中华肥胖与代谢病电子杂志, 2024, 10(03): 193-199.
[14] 崔磊, 徐东升. 减重手术治疗肥胖患者胰岛素抵抗的研究进展[J/OL]. 中华肥胖与代谢病电子杂志, 2024, 10(02): 127-132.
[15] 谭莺, 雷普润, 莫子健, 陈图锋, 陈燕铭. 减重代谢手术在糖胖病治疗中的应用及效果分析[J/OL]. 中华肥胖与代谢病电子杂志, 2024, 10(01): 9-14.
阅读次数
全文


摘要